Bliss GVS Pharma (506197) Q4 11/12 earnings summary

Executive summary

• FY12 total income rose 28% to ₹28,287.55 lakh; PBT increased 50% to ₹7,971.25 lakh, while PAT reached ₹5,282.90 lakh.

• Differentiated portfolio spans branded anti-malarials, suppositories, pessaries and women’s contraceptives; exports accounted for ~95% of revenue, led by Africa.

• Growth priorities include new markets, institutional tenders, contract manufacturing, product launches and R&D investment.

Financial highlights

• Net sales increased to ₹26,667.49 lakh from ₹21,883.81 lakh; total income was ₹28,287.55 lakh versus ₹22,071.07 lakh.

• PBT rose to ₹7,971.25 lakh from ₹5,298.14 lakh; PAT increased to ₹5,282.90 lakh from ₹4,063.03 lakh.

• Other income was ₹1,620.05 lakh, including a ₹1,346.84 lakh foreign-exchange gain; reported earnings therefore included a substantial FX benefit.

• Operating cash flow was ₹7,802.80 lakh; cash and cash equivalents increased by ₹3,992.10 lakh to ₹5,790.40 lakh.

Outlook and guidance

• Priorities include extending branded anti-malarials into South Africa, Botswana and Ethiopia, entering institutional tenders, and taking suppositories and pessaries into new markets.

• Plans include expanding the Today brand in India, introducing antibiotics and cosmetics, pursuing contract manufacturing, and developing injectables and APIs through Bliss Indasi LifeScience.

• Investment in an R&D laboratory was planned to support new formulations and analytical development; EU and North American markets were identified as expansion opportunities.